People who have been using Ozempic have been complaining of a bizarre side-effect, which has been nicknamed 'Ozempic butt'. The phenomenon has swept the US and overseas, as people - including ...
Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...
Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...
A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...
An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look ...
Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.
We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...
Most Wall Street professionals obsess over short-term returns. However, patient individual investors who buy and hold leading stocks on the cusp of new growth trends could strike it rich.
Swiss biopharma company BioVersys said on Wednesday it had launched an initial public offering on the SIX stock exchange priced at 36 Swiss francs ($39.84) per share.
The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...
NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...